Contact | Sitemap | About Medicines Research Responsibility News Investors Careers Corporate History Timeline Home / About / Corporate History Timeline Senior Management Worldwide Operations Ethics Business Conduct Business Partnerships Corporate History Timeline Share 2016 June 2016 The U.S. Food and Drug Administration Approves Epclusa® the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection. April 2016 The U.S. Food and Drug Administration approves Descovy® a fixed-dose combination for HIV-1 infection. March 2016 The U.S. Food and Drug Administration approves Odefsey® a complete once-daily, single tablet regimen for HIV-1 infection. 2015 November 2015 The U.S. Food and Drug Administration approves Genvoya® a complete once-daily, single tablet regimen for HIV-1 infection. May 2015 Gilead acquires Copenhagen, Denmark-based EpiTherapeutics ApS. 2014 October 2014 The U.S. Food and Drug Administration approves Harvoni® for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults. September 2014 The U.S. Food and Drug Administration approves Tybost® for use in combination with other antiretroviral agents for the treatment of HIV-1 infection. The U.S. Food and Drug Administration approves Vitekta® as part of combination antiretroviral therapy in adults with HIV-1 infection. July 2014 The U.S. Food and Drug Administration approves Zydelig® (idelalisib) for the treatment of certain patients with relapsed chronic lymphocytic leukemia (CLL) in combination with rituximab and as monotherapy for patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) and small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies. 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1992 1991 1990 1987 About Gilead Senior Management Worldwide Operations Ethics Business Conduct Business Partnerships Corporate History Timeline Research Pipeline Clinical Trials Investigator Sponsored Research Medicines Request Information Consumer Product Safety Authorized Distributors of Record Product Approval Timeline Responsibility U.S. Patient Access Developing World Access Corporate Contributions Policy Perspectives Gilead Foundation News Press Releases Events Media FAQs Fact Sheets Media Inquiries Investors Recent News Corporate Governance Stock Information Financial Information SEC Filings Shareholder Center Annual Reports Email Alerts Investor FAQs Investor Contacts Investor Disclaimer Careers Pipeline Our Values Developing-World-Access Corporate-Contributions U.S. Benefits © 2009-2016 Gilead. All rights reserved. Terms of Use | Privacy Statements Product images shown do not represent actual size.